
|Articles|May 13, 2004
Drug treats PCa patients with bone metastases
Novartis offers zoledronic acid injection (ZOMETA) for the treatmentof patients with documented bone metastases from solid tumors, includingprostate cancer, in conjunction with standard antineoplastic therapy.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Sean P. Collins, MD, PhD, outlines the impact of rectal spacers for men with prostate cancer
2
ORIC-944 shows promise in combination with ARPIs for mCRPC
3
Jason Hafron, MD, recaps prostate cancer data from ESMO 2025
4
Community practice experience shows early efficacy, favorable safety with nadofaragene
5



















